Biogen Inc. (NASDAQ:BIIB) is one of the best drug stocks to buy right now. In a report released on September 12, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Biogen Inc. (NASDAQ:BIIB) and set a price target of $220.00. Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Biogen Inc. (NASDAQ:BIIB) reported total revenue of$2.6 billion in its fiscal Q2 2025 results, up 7% year-over-year. GAAP diluted EPS for the quarter reached $4.33, up 8% year-over-year. Non-G ...